Peptide Drugs R&D Gained Traction Over Past Decades, States Kuick Research in Its In-demand Report Available at MarketPublishers.com

01 Jun 2017 • by Natalie Aster

LONDON – In the past few years, peptides have become one of the essential classes of therapeutic molecules developed by diverse pharma and biotech companies to achieve a targeted drug discovery for some illnesses. There are 688 peptide based therapeutics in development, with over 100 peptide based drugs being marketed to date. 

Due to their clinical high safety and efficacy profiles, R&D of peptide drugs has gained good momentum over the past decades. This causes pharmacos to pour more money into this segment to come out with competitive products for moving them to the market. Owing to a significant volume of disease indications these products hole potential to grab large market shares and produce huge revenues. Hence, newer peptide based drugs are coming into the global market, with others being at various clinical trial stages and set to get marketing approval in the short run. Meantime, the level of competition with drugs belonging to other categories for the identical disease indication is projected to be higher as time passes in this segment.

The market size of the peptide drugs is anticipated to expand several folds in the short run as more novel, innovative drugs for manifold indications will likely be introduced in market in the years to come.

Comprehensive market research study “Global Peptide Therapeutics Market & Clinical Trials Insight 2022” prepared by Kuick Research provides in-depth insights and analysis on the different clinical and non-clinical aspects relative to the global peptide drug sector development.

The research covers a revolution of peptide therapeutics, offers a comparison of peptides versus small molecules and protein biologics, discusses the fundamentals of peptide therapeutics. It categorises the peptide therapeutics by applications and indications. The study analyses the global peptide therapeutics market, by administration, covering current trends in RoA and over the peptide products. The report sheds light on the peptides clinical trials based on phase, indication and company. It gives deep insights into 688 peptide drugs in development; provides in-depth clinical and patent insights into 119 marketed products. Furthermore, a future outlook for the world peptide therapeutics market is also provided.

More comprehensive market reports by Kuick Research are offered at this page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com